Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine

使用抗血管生成纳米药物治疗哮喘的方法

• 批准号: 8618918
• 负责人: Gregory M Lanza
• 金额: $ 66万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-09 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8618918
• 关键词: Acute; Adult; Affect; American; Angiogenesis Inhibitors; Asthma; Atherosclerosis; Basement membrane; Blood Volume; Blood flow; Caring; Chronic; Collaborations; Development; Disease; Doctor of Philosophy; Dose; Economic Burden; Edema; Elements; Fluorocarbons; Glucocorticoids; Health Care Costs; Healthcare Systems; Histopathology; Home Care Services; Hospitalization; Hyperplasia; Image; Infiltration; Inflammatory; Lipase; Lung; Lung diseases; Malignant Neoplasms; Modeling; Molecular; Molecular Biology; Pathologic; Patients; Pharmaceutical Preparations; Pharmacodynamics; Phospholipids; Physiology; Pre-Clinical Model; Prodrugs; Rattus norvegicus; Research; Respiratory physiology; Role; Severities; Smooth Muscle; Staging; Steroids; Stratification; Structure; Symptoms; Therapeutic Agents; airway epithelium; airway inflammation; airway obstruction; airway remodeling; angiogenesis; antiangiogenesis therapy; base; density; design; eosinophil; experience; fumagillin; functional status; hemodynamics; improved; lung development; molecular imaging; nanomedicine; nanoparticle; nanotherapy; novel; professor; pulmonary function; respiratory; response to injury; spatiotemporal; standard of care; theranostics

DESCRIPTION (provided by applicant): Asthma is a chronic inflammatory lung disease that affects an estimated 23 million Americans (16 million adults), 12 million of whom experience at least one asthma attack annually. The symptoms of asthma cause significant economic burden on the healthcare systems ($18B in 2008) as well as dramatic impact on the quality of patients' lives. Asthma is characterized by airway inflammation and edema. Recently, the long recognized increase in airway wall microvessel density and expanded blood volume have been suggested to contribute significantly to lung function. This project combines the recognized expertise of Professor Elizabeth Wagner, PhD (PI) in pulmonary angiogenesis physiology and Professor Gregory M. Lanza, MD PhD (PD/PI), whose nanomedicine-based molecular imaging and therapy is well known, particularly in the context of angiogenesis in cancer and atherosclerosis. The overarching hypotheses of this proposal are to use nanomedicine approach to noninvasively characterize bronchial angiogenesis (new vessel formation), to deliver acute antiangiogenic therapy to reduce airway remodeling and improve pulmonary function, and to maintain the acute benefits of this new treatment with standard-of-care low dose steroids.

描述（由申请人提供）：哮喘是一种慢性炎症性肺部疾病，影响约2300万美国人（1600万成年人），其中1200万人每年至少经历一次哮喘攻击。哮喘的症状对医疗保健系统产生了重大的经济负担（2008年为18B美元），并对患者生活的质量产生了巨大影响。哮喘的特征是气道炎症和水肿。最近，已经建议长期公认的气道壁微血管密度和扩大的血容量增加，从而对肺功能产生显着贡献。 该项目结合了Elizabeth Wagner教授，肺血管生成生理学博士学位（PI）的公认专业知识，以及Gregory M. Lanza教授，医学博士学位（PD/PI），其基于纳米医学的分子成像和治疗是众所周知的，尤其是在癌症和癌症中的血管生成。该提案的总体假设是使用纳米医学方法来表征支气管血管生成（新血管形成），以提供急性的抗血管生成疗法来减少气道重塑并改善肺功能，并维持这种具有这种新的治疗方法的急性益处。